Immunic, Inc. (IMUX)
7.96
-0.68
(-7.87%)
USD |
NASDAQ |
Oct 02, 16:00
7.95
-0.01
(-0.13%)
After-Hours: 20:00
Immunic Enterprise Value : -45.92M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | -45.92M |
| October 01, 2026 | -36.64M |
| September 30, 2026 | -27.64M |
| September 29, 2026 | -32.96M |
| September 28, 2026 | -24.77M |
| September 25, 2026 | -27.02M |
| September 24, 2026 | -27.36M |
| September 23, 2026 | -26.68M |
| September 22, 2026 | -6.625M |
| September 21, 2026 | -6.761M |
| September 18, 2026 | -9.626M |
| September 17, 2026 | -13.31M |
| September 16, 2026 | -16.45M |
| September 15, 2026 | -13.04M |
| September 14, 2026 | -1.303M |
| September 11, 2026 | 1.289M |
| September 10, 2026 | 7.020M |
| September 09, 2026 | 11.80M |
| September 08, 2026 | 19.30M |
| September 04, 2026 | 24.35M |
| September 03, 2026 | 19.57M |
| September 02, 2026 | 39.77M |
| September 01, 2026 | 44.41M |
| August 31, 2026 | 61.05M |
| August 28, 2026 | 55.59M |
| Date | Value |
|---|---|
| August 27, 2026 | 67.87M |
| August 26, 2026 | 70.47M |
| August 25, 2026 | 69.51M |
| August 24, 2026 | 70.06M |
| August 21, 2026 | 70.60M |
| August 20, 2026 | 65.15M |
| August 19, 2026 | 69.92M |
| August 18, 2026 | 76.06M |
| August 17, 2026 | 64.19M |
| August 14, 2026 | 64.60M |
| August 13, 2026 | 71.69M |
| August 12, 2026 | 62.83M |
| August 11, 2026 | 56.69M |
| August 10, 2026 | 37.86M |
| August 07, 2026 | 40.59M |
| August 06, 2026 | 43.86M |
| August 05, 2026 | 36.63M |
| August 04, 2026 | 37.17M |
| August 03, 2026 | 37.86M |
| July 31, 2026 | 36.08M |
| July 30, 2026 | 36.36M |
| July 29, 2026 | 23.53M |
| July 28, 2026 | 27.49M |
| July 27, 2026 | 33.90M |
| July 24, 2026 | 28.17M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.551B |
| Sionna Therapeutics, Inc. | 18.79M |
| Alnylam Pharmaceuticals, Inc. | 29.06B |
| Savara, Inc. | 845.34M |
| Vericel Corp. | 1.987B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -34.10M |
| Total Expenses (Quarterly) | 34.10M |
| EPS Diluted (Quarterly) | -0.8021 |
| Earnings Yield | -60.38% |
| Normalized Earnings Yield | -60.37 |